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Background:  Dipeptidyl peptidase 4 (DPP-4, also known as CD26) binds with adenosine deaminase (ADA) to activate T lym-
phocytes. Here, we investigated whether ADA activity is specifically affected by treatment with DPP-4 inhibitor (DPP4I) com-
pared with other anti-diabetic agents. 
Methods:  Fasting ADA activity, in addition to various metabolic and biochemical parameters, were measured in 262 type 2 dia-
betes mellitus (T2DM) patients taking various anti-diabetic agents and in 46 non-diabetic control subjects.
Results:  ADA activity was increased in T2DM patients compared with that in non-diabetic control subjects (mean±standard 
error, 23.1±0.6 U/L vs. 18.6±0.8 U/L; P<0.05). ADA activity was correlated with fasting plasma glucose (r=0.258, P<0.05), 
HbA1c (r=0.208, P<0.05), aspartate aminotransferase (r=0.325, P<0.05), and alanine aminotransferase (r=0.248, P<0.05). 
Compared with the well-controlled T2DM patients (HbA1c<7%), the poorly controlled group (HbA1c>9%) showed signifi-
cantly increased ADA activity (21.1±0.8 U/L vs. 25.4±1.6 U/L; P<0.05). The effect of DPP4I on ADA activity in T2DM patients 
did not differ from those of other oral anti-diabetic agents or insulin. T2DM patients on metformin monotherapy showed a low-
er ADA activity (20.9±1.0 U/L vs. 28.1±2.8 U/L; P<0.05) compared with that of those on sulfonylurea monotherapy.
Conclusion:  Our results show that ADA activity is increased in T2DM patients compared to that in non-diabetic patients, is 
positively correlated with blood glucose level, and that DPP4I has no additional specific effect on ADA activity, except for a gly-
cemic control- or HbA1c-dependent effect.
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INTRODUCTION
Glucagon-like peptide-1 (GLP-1) [1,2], an incretin, promotes 
insulin secretion in a glucose concentration-dependent man-
ner in pancreatic beta cells [3], inhibits glucagon secretion in 
alpha cells [4], decreases the gastric discharge rate [5], and 
mediates appetite suppression [6]. However, because GLP-1 is 
rapidly degraded by dipeptidyl peptidase-4 (DPP-4), oral 
DPP-4 inhibitor (DPP4I) drugs and GLP-1 analogues have 
been developed to overcome the GLP-1 degradation effect in 
the treatment of diabetes [7].
  DPP-4, also known as CD26 or adenosine deaminase (ADA) 
binding protein, is a cellular membrane ectopeptidase in the 
prolyl oligopeptidase family [8,9]. Mammalian endothelial 
and epithelial cells generally express DPP-4; it is particularly 
abundantly expressed in the intestines, bone marrow, kidney, 
and liver. The enzymatic function of this molecule is not limit-
ed to direct action upon various substrates; it is also involved 
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in the regulation of cellular functions through interactions with 
various extracellular substrates [8,10]. DPP-4 is also expressed 
in the cells of the immune system, especially in T cells, in which 
it interacts with other signal transduction pathways (CD3) and 
acts as a co-stimulator of T cell (particularly CD4
+ T cell); the 
promotion of T-cell responses to foreign antigens, initial signal 
transduction, increased cytokine secretion, promotion of cell 
proliferation, increased expression of active T-cell markers 
(CD25, CD71, and CD69), promotion of effector cell differen-
tiation, increased cellular mobility, and many other actions [8-
10]. After new anti-diabetic drugs that selectively inhibit DPP-
4 were introduced and administered to diabetic patients, there 
were several reports that DPP4I might increase the incidences 
of some infectious diseases (e.g., nasopharyngitis and urinary 
tract infection), so further experimental and clinical studies 
are needed to determine the effects of DPP-4 on immune cell 
function [11-13]. One alleged side effect of DPP-4 inhibition 
is the nonspecific inhibition of DPP-8 and DPP-9. However, 
according to a recent study, high doses of vildagliptin, produc-
ing nearly complete inhibition of DPP-8 and DPP-9 in vivo, 
yielded no toxicities in rodents [14]. Therefore, further studies 
are required regarding the side effects of DPP4Is.
  DPP-4 can also bind with ADA. Since ADA degrades ade-
nosine, which inhibits the proliferation of T cells, this interac-
tion of DPP-4 with ADA and the rearrangement of ADA on 
cell membrane can lead to the increase in T-cell proliferation 
and cytokine synthesis due to ADA activity on the cell mem-
brane [15-17].
  ADA is an enzyme that converts adenosine into inosine 
through an irreversible deamination reaction [18]. Previous 
studies have reported that the highest ADA activity was ob-
served in the lymphoid and fatty tissues, liver, skeletal muscle, 
and heart, although the activity was widely distributed in most 
organs [19,20]. An increase in ADA activity in type 2 diabetic 
(T2DM) patients has been reported [21-23]. While the mech-
anism that increases serum and tissue ADA activity is not well 
known, with higher ADA activity in insulin-sensitive tissues, 
the level of adenosine, which increases glucose uptake into cells, 
will be reduced [24]. Thus, if ADA activity is suppressed, insu-
lin sensitivity may be improved, and cellular proliferation, in-
flammation, and T-cell activity, all of which are associated with 
the pathophysiology of insulin resistance, can also be affected. 
Therefore, insulin resistance may have an important relation-
ship with ADA activity. However, it is difficult to conclude 
whether changes in ADA activity are the cause or result of ac-
tual insulin resistance [25,26]. In addition to its association 
with diabetes, serum ADA activity is also increased in patients 
with liver cirrhosis as well as in patient with infectious diseases 
such as hepatitis, tuberculosis, brucellosis, and typhoid fever 
[27,28].
  Studies of the many functions of DPP-4, particularly those 
related to T-cell function, were performed prior to the devel-
opment of the DPP-4 selective inhibitor. As such, some of those 
studies used non-selective DPP inhibitors with low specificity 
and could have non-specific study results due to inhibition of 
other isoforms of DPPs in addition to DPP-4 [14,29]. 
  Since ADA activity is associated with T-cell activity and in-
sulin resistance and can bind with DPP-4, in the present study, 
we measured serum ADA activity in T2DM patients to evalu-
ate the relationship between serum ADA activity and various 
clinical and metabolic parameters including inflammatory 




The measurement of ADA activity was performed in patients 
with type 2 diabetes (T2DM, n=262) who were outpatients or 
who were hospitalized to control their blood glucose levels. All 
of the patients were on their oral anti-diabetic medications or 
insulin injection for more than one month. Standard biochem-
ical, metabolic, and anthropometric measurements were also 
performed in the subjects. Non-diabetic healthy subjects who 
visited our hospital for health screenings or standard medical 
examinations were selected as the control group (Non-DM, 
n=46). Patients with type 1 diabetes, systemic infectious dis-
eases, systemic inflammatory diseases, viral or alcoholic liver 
disease, advanced cardiovascular disease or other acute dis-
eases, pregnant women, and patients with a glomerular filtra-
tion rate less than 60 mL/min/1.73 m
2 were excluded from this 
study.
  After receiving a summary of the purpose of this study, the 
participants provided consent, and this study was conducted 
after approval from the Jeju National University Hospital In-
stitutional Review Board (IRB No. #2009-11).
Methods
Examinations
Blood and urine tests were performed after at least eight hours 151
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of fasting, and microalbumin tests were calibrated to be mea-
sured with urinary creatinine concentration (urine albumin to 
creatinine ratio [UACR], mg/g of creatinine). For blood cell 
calculation tests, total lymphocytes were calculated using com-
plete blood cell count. High sensitivity C-reactive protein 
(hsCRP) and erythrocyte sedimentation rates (ESR) were mea-
sured as inflammation markers. Serum ADA activity was mea-
sured using UV spectrophotometry (Asan Pharmaceutical 
Co., Seoul, Korea). C-peptides were measured using a radioim-
munoassay. Glycated hemoglobin (hemoglobin A1c, HbA1c) 
was measured using ion exchange HPLC (Tosoh Co., Tokyo, 
Japan).
Statistical analysis
All technical data were expressed as means±standard errors, 
and statistical analysis was performed using the SPSS statisti-
cal program version 15.0 for Windows (SPSS Inc., Chicago, IL, 
USA). Clinical features in the control group and in T2DM pa-
tients were analyzed using independent sample t-tests, and 
Pearson’s bivariate correlation analysis was used to correlate 
each variable with ADA activity. We performed multivariate 
regression analysis using log-substituted ADA activity as the 
dependent variable. Additionally, T2DM patients were classi-
fied into smaller groups based on their glycemic control level, 
diabetes treatment medications, and liver function, and the 
differences in ADA activity among these smaller groups were 
also analyzed. Fasting plasma glucose (FPG) and HbA1c data 
was used to classify patients into three groups. The difference 
in ADA activities among the three groups was analyzed by us-
ing a one-way ANOVA test. The comparison of ADA activities 
according to diabetes treatment medication was performed 
using a one-way ANOVA test. The diabetic patients were di-
vided into three groups as follows: the DPP4I group who were 
taking DPP4I and metformin combination therapy, the other 
oral hypoglycemic agent group who were taking metformin 
and other oral anti-diabetic agent(s) except for DPP4I, and the 
insulin treatment group (insulin combination therapy or insu-
lin monotherapy groups). To clearly evaluate the efficacy of 
the DPP4Is, the differences in ADA activity and levels of in-
flammatory markers between the metformin only group and 
the metformin and DPP4I combination therapy group (DPP4I 
merged group) were also analyzed using independent sample 
t-tests. Additionally, in T2DM patients who were taking DP-
P4I, ADA activity and inflammatory markers were measured 
prior to administration of DPP4I and 8 to 12 weeks after and 
were compared using a paired t-test. The comparison of ADA 
activities according to statin therapy was also performed and 
independent sample t-tests were used to compare the groups; 
any statin therapy group vs. no statin therapy group. 
  When analyzing the effects of drug treatment, ADA activity 
may be affected secondary to the degree of glycemic control. 
Therefore, when needed, ADA activity was adjusted using 
HbA1c value and the ANOVA test was performed. 
  In patients with T2DM, even mild changes in liver function 
are considered to have any effect on ADA activity. Prati et al. 
[30] proposed upper normal limit values in men and women 
according to alanine aminotransferase (ALT) value. Here, 
among the T2DM patients, women with ALT values less than 
19 IU/L and men with ALT values less than 30 IU/L were 
placed in the normal liver function group (Normal ALT), those 
who were not in that group were classified into the dysfunc-
tional liver group (High ALT). The differences in ADA activity 
between two groups were analyzed using independent sample 
t-tests. P values less than 0.05 were considered statistically sig-
nificant.
RESULTS
Clinical characteristics of study subjects
The clinical characteristics of the study subjects are shown in 
Table 1. The FPG values of the T2DM group (n=262) and the 
control group (n=46) were 154.8±3.4 mg/dL and 104.5±2.6 
mg/dL (P<0.05), and the HbA1c of the T2DM group was sig-
nificantly higher than that of the control group (7.7±0.1% vs. 
6.2±0.1%, P<0.05). However, because some patients with im-
paired fasting glucose were included in the control group, FPG 
and HbA1c levels were slightly increased when compared to 
the values that would be expected for a group with completely 
normal glucose metabolism.
  Compared to the control group, ADA activity in T2DM pa-
tients was significantly higher (23.1±0.6 U/L vs. 18.6±0.8 U/L, 
P<0.05); the ADA activity range in the control group was 5.4 
to 30.8 U/L compared to an ADA activity range of 5.8 to 64.6 
U/L in the T2DM group. The ADA activity distributions in 
normal healthy subjects and T2DM patients showed consider-
able overlap (Table 1, Fig. 1).
ADA activity and the correlations among various variables
Regarding the correlations between ADA activity and other 
variables in all included experimental subjects, age, FPG, 152
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HbA1c, aspartate aminotransferase (AST), ALT, ESR, and se-
rum creatinine levels of both the control group and the T2DM 
patient group were highly correlated with ADA activity (Table 
2). In a multivariate regression analysis that included age, FPG, 
HbA1c, AST, ALT, ESR, and serum creatinine as input variables 
and log-substituted ADA activity as a dependent variable, age 
(β=0.164, P=0.028), FPG (β=0.259, P=0.004), HbA1c (β=
0.168, P=0.012), and AST (β=0.264, P=0.014) remained sig-
nificant.
Degree of glycemic control in patients with T2DM 
according to the ADA activity comparison
Patients with T2DM were classified into three groups, those 
Table 1. Baseline characteristics of the subjects
Characteristic Non-DM (n=46)  T2DM (n=262) 
Age, yr  57.8±2.0  60.1±0.7 
BMI, kg/m
2  24.9±0.8  25.9±0.3 
FPG, mg/dL  104.5±2.6  154.8±3.4
a
HbA1c, %  6.2±0.1  7.7±0.1
a
C-peptide, ng/mL  2.4±0.3  2.1±0.1 
hsCRP, mg/L  1.2±0.2  2.7±0.5 
ADA, U/L  18.6±0.8  23.1±0.6
a
Uric acid, mg/dL 5.0±0.3  5.2±0.2 
AST, IU/L  25.3±1.6  24.7±0.8 
ALT, IU/L  27.4±2.1  29.3±1.2 
BUN, mg/dL  14.9±0.8  16.2±0.3 
Creatinine, mg/dL  0.9±0.0  1.0±0.0
a
Total cholesterol, mg/dL 185.9±6.6  176.8±2.4 
Triglyceride, mg/dL 145.6±13.1  138.6±5.4 
HDL-C, mg/dL 48.7±2.1  47.2±0.8 
LDL-C, mg/dL 119.3±5.7  109.7±2.2 
γ-GTP, U/L  19.7±2.3  36.1±3.2 
WBC, ×10
3/uL  6.5±0.2  6.7±0.1 
ESR, mm/hr 10.2±1.3  12.4±1.0 
Lymphocyte, %  34.8±1.3  34.9±0.5 
Lymphocyte, n  2,040.6±137.8  2,242.7±52.8 
UACR, mg/g  75.0±29.0  108.2±14.4 
Data are presented as means±standard error. 
T2DM, type 2 diabetes mellitus; BMI, body mass index; FPG, fasting 
plasma glucose; ADA, adenosine deaminase; hsCRP, high sensitivity 
C-reactive protein; HDL-C, high density lipoprotein cholesterol; 
LDL-C, low density lipoprotein cholesterol; γ-GTP, gamma GTP; 
WBC, white blood cell; ESR, erythrocyte sedimentation rate; UACR, 
urine albumin to creatinine ratio.
aP<0.05 vs. Non-DM group.
Table 2. The correlations between serum ADA activity and 
other parameters in all subjects 
Parameter  Correlation coefficient (r)  P value 
Sex  0.061  0.287 
Age, yr 0.172   0.003
a 
BMI, kg/m
2  0.146  0.060 
FPG, mg/dL  0.258   0.000
a 
HbA1c, % 0.208   0.001
a 
C-peptide, ng/mL  0.005  0.948 
hsCRP, mg/L 0.019  0.741 
Uric acid, mg/dL -0.072  0.374 
AST, IU/L  0.325   0.000
a 
ALT, IU/L  0.248   0.000
a 
BUN, mg/dL 0.020  0.727 
Creatinine, mg/dL 0.116  0.046 
Total cholesterol, mg/dL  -0.062  0.292 
Triglyceride, mg/dL  -0.045  0.435 
HDL-C, mg/dL  -0.028  0.627 
LDL-C, mg/dL  -0.081  0.165 
γ-GTP, U/L  0.098  0.248 
WBC, ×10
3/μL  0.002  0.971 
ESR, mm/hr  0.220   0.003
a 
Lymphocyte, %  0.009  0.882 
Lymphocyte, n 0.015  0.795 
UACR, mg/g 0.009  0.889 
ADA, adenosine deaminase; BMI, body mass index; FPG, fasting 
plasma glucose; hsCRP, high sensitivity C-reactive protein; HDL-C, 
high density lipoprotein cholesterol; LDL-C, low density lipoprotein 
cholesterol; γ-GTP, gamma GTP; WBC, white blood cell; ESR, eryth-
rocyte sedimentation rate; UACR, urine albumin to creatinine ratio.
aP<0.05.
Fig. 1. (A) The comparison of serum adenosine deaminase 
(ADA) activity levels (means±standard error) between non-
diabetic control subjects (Non-DM) and patients with type 2 
diabetes mellitus (T2DM). (B) Serum ADA activities show 
wide variations within each group. 
aP<0.05 vs. Non-DM sub-
jects.
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with HbA1c levels less than 7% (n=108), those with levels 
ranging from 7 to 9% (n=100), and those with levels greater 
than 9% (n=52). When the ADA activity levels of these groups 
were compared, the group with HbA1c level less than 7% had 
a significantly lower ADA activity compared to that of the 
groups with HbA1C levels between 7-9% and greater than 9% 
(21.1±0.8 U/L, 24.5±1.0 U/L, and 25.4±1.6 U/L for the less 
than 7%, 7-9%, and greater than 9% groups, respectively; P<
0.05). However, the ADA activities in the 7-9% and greater than 
9% HbA1c groups were not significantly different (P=0.849, 
Fig. 2A).
  T2DM patients were classified into three groups according 
to FPG level: less than 155 mg/dL (n=157), 155-212 mg/dL 
(n=66), and greater than 212 mg/dL (n=37). These groups 
were then analyzed for their ADA activity. The respective ADA 
activities were 21.5±0.7 U/L, 24.6±1.2 U/L, and 28.2±1.8 U/
L. The group with FPG less than 155 mg/dL and that with FPG 
greater than 212 mg/dL had significant differences between 
their ADA activity levels. There were no significant differences 
between the less than 155 mg/dL FPG group and the 155-212 
mg/dL FPG group (P=0.075) or between the 155-212 mg/dL 
FPG group and the greater than 212 mg/dL FPG group (P=
0.171, Fig. 2B).
Comparative ADA activity levels between the DPP4I 
treatment group and other treatment groups of T2DM 
patients 
T2DM patients were classified into three separate groups ac-
cording to treatment type. Thirty-four patients were placed in 
the DPP4I treatment group, 195 patients were in the other oral 
anti-diabetic agent group, and 33 patients were in the insulin 
combination therapy group. The ADA activity values for the 
three groups were 23.6±1.3 U/L, 22.5±0.7 U/L, and 27.3±1.8 
U/L, respectively. There was a significant difference between 
the other oral hypoglycemic agent group and the insulin com-
bination therapy group (P<0.05). There were no significant 
differences in ADA activity level between the DPP4I treatment 
group and the other oral hypoglycemic agent group (P=0.834) 
Fig. 2. The comparisons of serum adenosine deaminase 
(ADA) activity according to level of blood glucose control 
stratified by HbA1c (A) and fasting plasma glucose (FPG) val-
ues (B) in patients with type 2 diabetes mellitus. 
aP<0.05 vs. 
the group with HbA1c<7% according to one-way ANOVA 
test, 
bP<0.05 vs. the group with FPG <155 mg/dL according 
to one-way ANOVA test.
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Fig. 3. The comparisons of (A) adenosine deaminase (ADA) 
activity and (B) ADA activity adjusted for HbA1c according to 
the type of antidiabetic treatment that type 2 diabetes mellitus 
(T2DM) patients had been receiving for at least four weeks be-
fore the laboratory tests. The comparisons of (C) ADA activity 
and (D) ADA activity adjusted for HbA1c between a group on 
DPP-4 inhibitor (DPP4I)/metformin combination therapy 
and a group on metformin monotherapy in patients with 
T2DM. Comparisons of (E) ADA activity and (F) ADA activi-
ty adjusted for HbA1c between a group on metformin mono-
therapy and a group on sulfonylurea monotherapy in patients 
with T2DM. Vildagliptin 50 mg bid or sitagliptin 50-100 mg 
daily. Other oral hypoglycemic agents (OHAs), monotherapy 
or combination therapies including sulfonylurea, metformin, 
acarbose, or thiazolidinedione; Insulin, any insulin therapy 
with or without oral antidiabetic agent(s) except for DPP4I. 
aP<0.05 vs. other OHAs, 
bP<0.05 vs. the group on metformin 
monotherapy.
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or between the DPP4I treatment group and the insulin combi-
nation therapy group (P=0.278, Fig. 3A). When HbA1c level 
of these groups were compared, the insulin combination ther-
apy group had a significantly higher HbA1c level compared to 
those of two other groups (6.8±0.1%, 7.6±0.1%, and 8.9±0.3% 
for DPP4I treatment group, the other oral hypoglycemic agent 
group, and the insulin combination therapy group, respective-
ly; P<0.05). However, there was no significant difference in the 
ADA activity values that were adjusted for HbA1c among the 
three groups (Fig. 3B).
  The ADA activity results between the metformin mono-
therapy group (n=51) and the DPP4I combination therapy 
group (n=34) did not differ significantly (20.9±1.0 U/L vs. 
23.6±1.3 U/L, P=0.09, Fig. 3C). In addition, there was no sig-
nificant difference in HbA1c level between the two groups 
(7.1±0.2% vs. 6.8±0.1%, P=0.285), and there was very little 
difference in the ADA activity values that were adjusted for 
HbA1c (Fig. 3D).
  In order to better understand the effects of metformin 
monotreatment on ADA activity, we made independent com-
parisons of the metformin monotreatment group (n=50) and 
the sulfonylurea monotreatment group (n=9). These results 
showed that, despite the small difference in HbA1c value be-
tween them (7.1±0.2% vs. 6.9±0.4%, P=0.624), the ADA ac-
tivity in the metformin monotreatment group was significant-
ly lower than that of the sulfonylurea monotreatment group 
(20.9±1.0 U/L vs. 28.1±2.8 U/L, P<0.05, Fig. 3E). This sug-
gests the possibility that metformin can directly influence ADA 
activity. Additionally, the ADA activity levels adjusted for 
HbA1c maintained a significant statistical difference (Fig. 3F).
ADA activity comparison before and after DPP4I treatment 
in T2DM patients
We measured HbA1c and ADA activity levels before DPP4I 
treatment and 8 to 12 weeks after treatment in a small sub-
group of the DPP4I treatment group (n=24). Despite the re-
ductions in the comparatively analyzed results of HbA1c (7.4± 
0.2% vs. 6.6±0.1%, P<0.05), ADA activity (24.7±1.7 U/L vs. 
23.0±1.6 U/L, P=0.154) showed no change (Fig. 4A). Addi-
tionally, ADA activity levels before and after DPP4I adminis-
tration were adjusted for HbA1c, but the comparatively ana-
lyzed results did not show a significant difference (3.4±0.2 U/
L/% vs. 3.5±0.2 U/L/%, P=0.347, Fig. 4B).
  These results suggest that ADA activity is unaffected by DP-
P4I administration regardless of glycemic control. Also, leu-
kocytes, lymphocyte count, lymphocyte percentage, ESR, and 
hsCRP before and after the administration of DPP4I were not 
significantly statistically different.
Comparison of ADA activity according to statin therapy in 
T2DM patients
T2DM patients were classified into two groups according to 
statin treatment or not. Between the statin-treated (n=114) 
and non-treated (n=146) groups, the comparatively analyzed 
results showed little difference with regard to HbA1c level 
(7.7±0.1% vs. 7.7±0.1%, P=0.851) or FPG level (154.0±5.7 
mg/dL vs. 155.6±4.2 mg/dL, P=0.833). However, ADA activi-
ty was significantly lower in the statin-treated group than in 
the group not treated with statins (22.0±0.8 U/L vs. 24.2±0.9 
U/L, P<0.05, Fig. 5A). Even after ADA activity was adjusted 
for HbA1c, there was a strong tendency toward a lower ADA 
activity in the statin-treated group compared to the non-treat-
ed group (P=0.086, Fig. 5B). Additionally, the comparable 
levels of AST, ALT, and hsCRP between the two groups sug-
Fig. 4. The comparisons of (A) adenosine deaminase (ADA) 
activity and (B) ADA activity adjusted for HbA1c from before 
and after the addition of DPP-4 inhibitor (DPP4I) therapy to 
an existing regimen of metformin monotherapy (2 g/day) in 
patients with type 2 diabetes mellitus. Vildagliptin 50 mg bid 
or sitagliptin 50-100 mg daily. ADA activity was measured be-
fore and after treatment with vildagliptin 50 mg bid or sita-
gliptin 50-100 mg daily for at least 8 to 12 weeks.
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Fig. 5. The comparisons of (A) adenosine deaminase (ADA) 
activity and (B) ADA activity adjusted for HbA1c between pa-
tients with type 2 diabetes mellitus on statin therapy and those 
not on statin therapy. 
aP<0.05 vs. no statin.
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gest that ADA activity could be directly inhibited by statin.
Comparison of ADA activity according to liver function in 
T2DM patients
We applied the upper limit of the normal values of liver func-
tion tests in healthy male and female subjects proposed by Pra-
ti et al. [30] to patients with T2DM, divided them according to 
ALT value into normal ALT and high ALT groups, and their 
ADA activities were compared. In female patients, ADA activ-
ity in the normal ALT group (n=37) was significantly lower 
than that in the high ALT group (n=75) (21.8±1.2 U/L vs. 
26.0±1.1 U/L, P<0.05). The same was true in male patients 
(20.9±1.0 U/L vs. 24.2±1.3 U/L, P<0.05). All T2DM patients 
were classified as normal ALT (n=125) or high ALT (n=128), 
and a comparison of ADA activity showed that the normal ALT 
group had significantly lower ADA activity than did the high 
ALT group (21.2±0.8 U/L vs. 25.9±0.8 U/L, P<0.05).
  T2DM patients with normal liver function were classified 
into the following groups according to FPG level: less than 155 
mg/dL (n=74), 155–212 mg/dL (n=34), and greater than 212 
mg/dL (n=17). The ADA activities of the groups were 19.7±
1.0 U/L, 22.5±1.4 U/L, and 25.3±2.5 U/L, respectively, and 
there was a considerable difference in the ADA activity between 
the group with FPG less than 155 mg/dL and the group with 
FPG greater than 212 mg/dL.
The comparisons of ADA activity and other factors in 
T2DM patients 
T2DM patients were separated into subgroups based on sever-
al variables, including hsCRP level (hsCRP<3 mg/L and ≥3 
mg/L), white blood cell count (<10.0×10
3/μL group and 
≥10.0×10
3/μL), and lymphocyte percentage (<44% and 
≥44%), and comparisons of ADA activity were made for each 
pair of subgroups. ADA activity did not show a significant dif-
ference between the groups with high and low levels of each 
variable. 
DISCUSSION
Because DPP-4 is an ADA-binding partner and ADA is closely 
related to T lymphocyte function [9] and insulin resistance, in 
the present study, we measured ADA activity in T2DM patients 
to evaluate whether there is an effect from selective DPP4I 
treatment and whether ADA activity is affected by other thera-
peutic drugs. According to our results, ADA activity in T2DM 
patients was significantly higher than that in the control group, 
and had positive correlations with both FPG and HbA1c.
  T2DM patients were also classified according to drug treat-
ment type, and the ADA activity analysis results showed that 
the DPP4I treatment group did not have a significant differ-
ence in ADA activity from that of the other oral agent group 
or from that of the insulin treatment group. Also, the compari-
son of ADA activity between the metformin monotherapy 
group and the DPP4I combination therapy group showed no 
significant difference. Even when ADA activity was compared 
before and after DPP4I treatment, and regardless of glycemic 
control status, DPP4I treatments were confirmed not to have 
any specific effect on ADA activity. Conversely, when HbA1c 
had a tendency to be lower, ADA activity remained propor-
tional, which suggests that ADA activity can increase as a re-
sult of selective DPP4I treatment. At least, in the present study, 
it was confirmed that DPP4I did not reduce ADA activity. One 
of the possible reasons that ADA activity was not affected by 
selective DPP4Is is evident through a recent analysis of the 
DPP-4 protein structures which revealed the active sites of 
DPP-4, active binding site of DPP4Is, and ADA binding site. 
Since the actions of these small molecules with selective DPP-
4 inhibitory actions are limited to the DPP-4 catalytic pocket, 
the selective DPP4Is are unlikely to affect conformational 
structure of the DPP-4 protein, its dimerization, ant its inter-
actions with other binding partners [31]. However, recent cel-
lular and animal experimental results have shown that the 
mobility of CD4
+ T lymphocytes derived from the spleens of 
non-obese diabetic (NOD) mice is increased by soluble DPP-4 
(sDPP-4) [32]. Also, sitagliptin suppressed sDPP-4-induced 
CD4
+ T cell infiltration in the islets. So, the diabetes reduction 
by sitagliptin treatment in NOD mice seems to involve a re-
duction in T-cell mobility, and then the reduction of insulitis 
[32]. Thus, although selective DPP4Is did not have an effect on 
ADA activity, more studies of the effects of DPP4Is on T-cell 
functions are needed.
  ADA activity comparisons of oral hypoglycemic monotreat-
ment groups showed that ADA activity was significantly lower 
in the metformin monotreatment group than it was in the sul-
fonylurea monotreatment group. Metformin decreases insulin 
resistance, so ADA activity is expected to decrease in conjunc-
tion with metformin therapy. Reports from one study con-
ducted on red blood cell lysates showed that metformin did 
not directly inhibit ADA activity [33]. The ADA activity in the 
statin-treated group was significantly lower when compared to 156
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the activity in the non-treated group; this difference was not 
related to glycemic control, but statin itself may potentially af-
fect ADA activity. In previous studies, it was reported that 
simvastatin-treated groups have significantly reduced ADA 
activity [34]; however, the exact mechanism still remains un-
clear. Statin’s lipid-lowering effects and various other effects 
such as an anti-inflammatory actions, T-cell differentiation in-
hibition, TNF-α inhibition, and other immune regulatory ef-
fects [35-37] may be considered to have an effect on ADA ac-
tivity.
  In line with previous reports done by other researchers, ADA 
activity in T2DM patients in the present study was significant-
ly higher than that in the control group [21-23]. Moreover, 
compared to that of T2DM patients with relatively good glyce-
mic control, the ADA activity in T2DM patients with poor 
glycemic control was significantly lower. These results are con-
sistent with those reported by Hoshino et al. [38].
  Although subjects with active liver diseases were excluded 
from this study, the patients with even mild liver dysfunction 
which seemed to be related to metabolic syndrome, had sig-
nificantly higher ADA activity regardless of glycemic control. 
The differences in ADA activity corresponding to differences 
in the AST and ALT levels that reflect liver dysfunction are 
consistent with the reports from other studies [21,30]. A cor-
relation between γ-GTP and ADA activity had also been re-
ported [21], but was not shown to be statistically significant in 
the present study. When the ADA activity in diabetic patients 
with normal liver function was analyzed, the results showed 
that patients with poor glycemic control had significantly high-
er ADA activity. In the analysis of all patients and several sub-
groups, ADA activity did not have a significant correlation 
with hsCRP, white blood cell count, or lymphocyte count.
  The limitations of this study were as follows: 1) ADA activi-
ty differences based on glycemic control level, treatment med-
ications and liver functions were compared in T2DM patients 
through a simple cross-sectional study, 2) comparisons before 
and after medical treatments were not performed, 3) because 
national health insurance does not cover DPP4I monotreat-
ment, patients undergoing metformin baseline maintenance 
treatment who were treated with an additional DPP4I were 
classified into the DPP4I treatment group and analyzed as 
such. Additionally, the control group was composed of non-
diabetic adults, and patients with diabetes were excluded in 
the group; however, adults with impaired fasting glucose may 
have been included in the control group.
  In conclusion, compared to the control group, ADA activity 
in T2DM patients was higher. When glycemic control was rel-
atively good, ADA activity was low. However, although neither 
ADA activity nor inflammatory-response-related variables 
changed with DPP4I treatment regardless of changes in glyce-
mic control. 
  Thus, the results of this study suggest that the selective DP-
P4Is currently used by diabetic patients do not have any effect 
on the non-enzymatic action of DPP-4. In addition to this study 
focused on ADA activity, additional studies are needed to 
evaluate the effects of selective DPP4Is on other physiologic 
functions related to the non-enzymatic action of DPP-4.
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